10.70
前日終値:
$11.01
開ける:
$11.17
24時間の取引高:
2.25M
Relative Volume:
1.06
時価総額:
$1.18B
収益:
$139.71M
当期純損益:
$-209.36M
株価収益率:
-3.6149
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
-22.07%
1か月 パフォーマンス:
-7.12%
6か月 パフォーマンス:
-50.94%
1年 パフォーマンス:
-51.30%
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
730 THIRD AVENUE, NEW YORK, MA
SNDX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SNDX
Syndax Pharmaceuticals Inc
|
10.70 | 1.18B | 139.71M | -209.36M | -160.60M | -2.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-24 | 開始されました | UBS | Buy |
2024-06-28 | 開始されました | Jefferies | Buy |
2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
2023-12-22 | 開始されました | Mizuho | Buy |
2023-10-25 | 開始されました | BofA Securities | Buy |
2023-10-11 | 開始されました | Goldman | Buy |
2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
2023-07-11 | 開始されました | Guggenheim | Buy |
2023-04-17 | 再開されました | BTIG Research | Buy |
2023-01-31 | 開始されました | Stifel | Buy |
2023-01-03 | 開始されました | JP Morgan | Overweight |
2022-07-28 | 再開されました | B. Riley Securities | Buy |
2022-04-11 | 開始されました | H.C. Wainwright | Buy |
2022-02-15 | 開始されました | Goldman | Buy |
2021-06-04 | 再開されました | Robert W. Baird | Outperform |
2021-05-25 | 開始されました | Citigroup | Buy |
2021-02-18 | 開始されました | B. Riley Securities | Buy |
2020-12-03 | 開始されました | Stifel | Buy |
2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
2019-01-04 | 開始されました | Robert W. Baird | Outperform |
2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
2017-03-16 | 開始されました | FBR & Co. | Outperform |
2017-03-02 | 開始されました | Instinet | Buy |
2016-10-07 | 開始されました | Guggenheim | Buy |
2016-03-28 | 開始されました | Citigroup | Buy |
2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
What is B. Riley's Forecast for SNDX Q2 Earnings? - MarketBeat
Bayesian Capital Management LP Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Marshall Wace LLP Sells 977,280 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Algert Global LLC Buys 310,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - Yahoo Finance
Avidity Partners Management LP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $17.00 - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at Guggenheim - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Crestline Management LP Grows Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Announces Participation in May Investor Conferences - The Manila Times
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results - simplywall.st
SNDX: Syndax Reveals Significant Phase 2 Trial Results for Revumenib | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Average Target Price from Analysts - MarketBeat
Syndax Announces Publication of Pivotal Revumenib Data in - GlobeNewswire
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - Yahoo Finance
Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call - TipRanks
SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenhei - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News - GuruFocus
Scotiabank raises Syndax stock target to $17 on strong sales By Investing.com - Investing.com Canada
Syndax (SNDX) Price Target Increased by BofA Following Promising Updates | SNDX Stock News - GuruFocus
BofA raises Syndax stock price target to $26 on strong Q1 update - Investing.com Canada
Syndax Pharmaceuticals Q1 Loss Widens - marketscreener.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highligh - GuruFocus
SNDX Reports Strong Revenue and Cash Position, Focuses on Growth - GuruFocus
Syndax Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2025 EPS estimates - Investing.com Canada
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax: Q1 Earnings Snapshot - MySA
Syndax Pharmaceuticals earnings beat by $0.26, revenue topped estimates - Investing.com Canada
Syndax Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.98 Beats Estimates, Revenue Surges to $20 Million - GuruFocus
Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong - Investing.com India
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong By Investing.com - Investing.com South Africa
SNDX Reports Impressive Q1 Revenue, Exceeds Market Expectations | SNDX Stock News - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Revenue $20M, vs. FactSet Est of $15.6M - marketscreener.com
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday - MarketBeat
Adage Capital Partners GP L.L.C. Sells 195,760 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
(SNDX) Investment Analysis - news.stocktradersdaily.com
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):